<SEC-DOCUMENT>0001213900-26-061765.txt : 20260528
<SEC-HEADER>0001213900-26-061765.hdr.sgml : 20260528
<ACCEPTANCE-DATETIME>20260528080518
ACCESSION NUMBER:		0001213900-26-061765
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260528
FILED AS OF DATE:		20260528
DATE AS OF CHANGE:		20260528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36578
		FILM NUMBER:		261028609

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Enlivex Therapeutics Ltd.
		DATE OF NAME CHANGE:	20190326

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0292428-6k_enlivex.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 6-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the month of: May 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission file number: 001-36578</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ENLIVEX LTD.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>14 Einstein Street, Nes Ziona, Israel 7403618</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On May 28,
2026, Enlivex Ltd.,</FONT> a company organized under the laws of the State of Israel, <FONT STYLE="background-color: white">issued a press
release providing an update on its RAIN token holdings. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea029242801ex99-1.htm"><FONT STYLE="font-size: 10pt">Press Release</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">Enlivex Ltd.</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Oren Hershkovitz</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Oren Hershkovitz<BR>
Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: May 28, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea029242801ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="ea029242801_ex99-1img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Enlivex Treasury Portfolio Update: RAIN Holdings
Valued at Approximately $1.16 Billion;<BR>
Rain Foundation Appoints Industry Leaders to Advisory Board</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens
with a total value of approximately $1.16 billion.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify">Separately, the Rain Foundation recently announced the appointment
of five industry leaders to its advisory board, supporting the next phase of growth of the Rain protocol, the primary digital asset in
Enlivex&rsquo;s prediction markets treasury strategy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Nes-Ziona, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq:
ENLV, &ldquo;Enlivex&rdquo; or the &ldquo;Company&rdquo;), a quality longevity company powered by a prediction markets treasury, today
provided an update on its RAIN token holdings. As of May 27, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately
$1.16 billion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Separately, the Rain Foundation, the administrative body overseeing
the Rain protocol, recently announced the appointment of five industry leaders to its advisory board. The new appointments include Stefan
Rust, former Chief Executive Officer of Bitcoin.com and a prominent entrepreneur in the blockchain industry; Dennis Liu, known as Virtual
Bacon, a crypto analyst and content creator specializing in technical analysis and investment research; Route2FI, a financial writer and
crypto influencer known for in-depth analysis of decentralized finance strategies and macroeconomic trends; David Airey, Chief Operating
Officer of Crypto Banter, a major live-streaming media platform focused on digital asset markets; and Danny Frishman, a veteran technology
entrepreneur with an extensive track record in blockchain and digital innovation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">According to the Rain Foundation, the Rain protocol has achieved significant
traction since launching its open beta, with more than 29,000 users and more than 100 million RAIN tokens burned through its buyback-and-burn
mechanism, as of April 27, 2026. On May 27, 2026, the Rain Foundation announced a $100 million liquidity commitment to Rain&rsquo;s prediction
markets protocol. The increased liquidity currently positions Rain as the third-largest prediction market protocol globally by Total Value
Locked (TVL). Polymarket leads the prediction market category with approximately $450 million in TVL<SUP>1</SUP>, and Rain&rsquo;s $100
million liquidity commitment positions the protocol as the third-largest globally, alongside the category leaders.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Oren Hershkovitz, Ph.D., CEO of Enlivex, commented,
&ldquo;Our updated treasury position reflects Enlivex&rsquo;s strategic commitment to the prediction markets sector. We believe that
the continued progress of the Rain protocol ecosystem, including the current jump into the 3<SUP>rd</SUP> place in the leading prediction
markets league table with approximately $100MM in TVL<SUP>1</SUP>, compared with approximately $450MM for Polymarket, supports our long-term
view of RAIN as a core treasury asset.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Enlivex (Nasdaq: ENLV)</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Enlivex is a quality longevity company powered by a prediction markets
treasury. The Company is advancing Allocetra&trade;, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated
with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets
treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy
combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
https://dune.com/rain predictions/rain; https://defillama.com/protocols/prediction-market</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 34%; font-size: 10pt">Enlivex (Nasdaq: ENLV)</TD>
    <TD STYLE="width: 33%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: right; font-size: 10pt">www.enlivex.com</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><IMG SRC="ea029242801_ex99-1img1.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This press release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking
statements may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;projects,&rdquo; &ldquo;will,&rdquo;
&ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;target,&rdquo; &ldquo;has the potential to,&rdquo; &ldquo;goal,&rdquo;
and other words of similar meaning, including statements relating to the anticipated benefits of the Company&rsquo;s digital asset treasury
strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token;
the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects
of digital asset liquidity on the liquidity of the Company&rsquo;s ordinary shares; macroeconomic, political, and regulatory conditions
surrounding digital assets; the Company&rsquo;s plans for value creation and strategic positioning; market size and growth opportunities;
regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical
trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of,
and market opportunities for, ALLOCETRA&trade; programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Each forward-looking statement contained in this press release is subject
to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable
risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company&rsquo;s digital
asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company&rsquo;s
operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies;
risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity
of the Company&rsquo;s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to
increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and
technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes;
and those risks and uncertainties identified in the Company&rsquo;s filings with the Securities and Exchange Commission. The forward-looking
statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise
any of these statements, except as required by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ENLIVEX CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Shachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 34%; font-size: 10pt">Enlivex (Nasdaq: ENLV)</TD>
    <TD STYLE="width: 33%; text-align: center; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: right; font-size: 10pt">www.enlivex.com</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ea029242801_ex99-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029242801_ex99-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  G )T# 2(  A$! Q$!_\0
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M/&^M:SH/A)M=T^:'RK_2M)U/5)["5FM[]K2[BDMU /Z'J*_!'_@GQ_P<??\
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MS6MQ'>>._/T:YTV?S+&X\//;V)T*:%]-^P68M_(2;_@C;\$?!O\ P4<^ ?\
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MAXT\>V^A0O<22-%IVE:QXIU9-,M4*PV=I,MM B011(OUQ_P6>_Y)O_P;!_\
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M+/BAH'PW_;T^%^L>'O$/@#5_AG\!_BI\)V^*=C!K5FNK^&_%VHP?#WPWH/\
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M?[7]GO\ :V_;A\->&;GXC_LY_":'PVNN_ /PK\7[B$7_ ,,]W@>*VT5?B/\
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J-$EUJ;11/IFG?%2+3K>WT<^(M:CTRTL;:UM;&WOY+6WACMTABC** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
